Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial

Parker, C., Zhan, L., Cislo, P. et al. (6 more authors) (2017) Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. European Journal of Cancer, 71. C. pp. 1-6. ISSN 0959-8049

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Dates:
  • Published: 1 January 2017
  • Accepted: 17 October 2016
  • Published (online): 6 December 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 18 Jan 2017 16:09
Last Modified: 18 Jan 2017 16:16
Published Version: http://doi.org/10.1016/j.ejca.2016.10.020
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.ejca.2016.10.020

Share / Export

Statistics